Insulin precursors, their preparation, and dna sequences, expression vehicles and primers and a process for producing human insulin and analogues
Abstract
The invention relates to insulin precursors having the amino acid sequence B(1-29)-X₁-X₂-Y₂-Y₁-A(1-21) wherein B(1-29) are the 29 first amino acid residues of the B chain of human insulin, A(1-21) are the 21 amino acid residues of the A chain of human insulin, X₁ represents a peptide bond or one or more amino acid residues, X₂ represents Glu or Asp, and Y₁ and Y₂ each represent Lys or Arg, the positions A6 and A11, A7 and B7 and A20 and B19, respectively, being connected through sulphur bridges, and, optionally, one or more of the amino acid residues of chains B(1-29) and A(1-21) are substituted by another amino acid residue. The insulin precursors are prepared by culturing a yeast strain transformed with a replicable expression vehicle comprising a DNA sequence encoding the insulin precursor and isolating it from the culture medium. The insulin precursors can be converted into human insulin or insulin analogues by enzymatic treatment.
Term
Term ended
Projected expiry passed 20 June 2009, 17.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| EP0037255B1 | Cites | European Patent Office (EPO) | Y | Search report |
| EP0163529A1 | Cites | European Patent Office (EPO) | Y | Search report |
| EP0195691A1 | Cites | European Patent Office (EPO) | YD | Search report |
| EP0254516A2 | Cites | European Patent Office (EPO) | A | Search report |
34 members in 17 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 336188 | Denmark | – | |
| 336188 | Denmark | A | |
| DK19880003361 | – | – | – |
Members34
| Document | Office | Kind | |
|---|---|---|---|
| DK336188D0 | Denmark | D0 | |
| IE891976L | Ireland | L | |
| EP0347845A2 | European Patent Office (EPO) | A2 | |
| WO8912647A1 | World Intellectual Property Organization (WIPO) | A1 | |
| PT90897A | Portugal | A | |
| AU3860089A | Australia | A | |
| KR900701841A | Republic of Korea | A | |
| DK301090A | Denmark | A | |
| DK301090D0 | Denmark | D0 | |
| NO905470D0 | Norway | D0 | |
| NO905470L | Norway | L | |
| NZ229615A | New Zealand | A | |
| EP0347845A3This record | European Patent Office (EPO) | A3 | |
| JPH03505206A | Japan | A | |
| ZA894639B | South Africa | B | |
| AU618612B2 | Australia | B2 | |
| DK164456B | Denmark | B | |
| DK164456C | Denmark | C | |
| US5202415A | United States of America | A | |
| EP0347845B1 | European Patent Office (EPO) | B1 | |
| AT93239T | Austria | T | |
| DE68908491D1 | Germany | D1 | |
| DE68908491T2 | Germany | T2 | |
| US5324641A | United States of America | A | |
| ES2059627T3 | Spain | T3 | |
| PT90897B | Portugal | B | |
| NO177499B | Norway | B | |
| IE64303B1 | Ireland | B1 | |
| NO177499C | Norway | C | |
| CA1337976C | Canada | C | |
| JP2766999B2 | Japan | B2 | |
| KR0140238B1 | Republic of Korea | B1 | |
| FI102294B | Finland | B | |
| FI102294B1 | Finland | B1 |
48 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Patent ceasedCeasedPL | PL | CH | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| No opposition filedOpposition26N | 26N | EP | |
| Lu: last paid annual feeEPTA | EPTA | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Validation in greece3009802FG4A | FG4A | GR | |
| Fr: translation filedET | ET | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Main classification (correction)RHK1 | RHK1 | EP | |
| Designated contracting statesAK | AK | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0347845
- Publication, DOCDB
- 0347845
- Publication, EPODOC
- EP0347845
- Application
- 111221
- Application, DOCDB
- 89111221
- Application, EPODOC
- EP19890111221
Titles3
- German
- Insulinvorläufer, deren Herstellung und DNA-Sequenzen, Expressionsvehikel und Primer und ein Prozess zur Herstellung von Humaninsulin und Analoge
- English
- INSULIN PRECURSORS, THEIR PREPARATION, AND DNA SEQUENCES, EXPRESSION VEHICLES AND PRIMERS AND A PROCESS FOR PRODUCING HUMAN INSULIN AND ANALOGUES
- French
- Précurseurs d'insuline, leur préparation et séquences d'ADN, véhicules et primers d'expression, et procédé pour la production d'insuline humaine et d'analogues
Classification
- CPC, 2
- C07K14/62
- A61K38/00
- IPC, 7
- C12N15 09
- A61K38 00
- C07K14 575
- C07K14 62
- C12N15 17
- C12P21 02
- C12R1 865
Designated states13
- Contracting states, 13
- Austria
- Belgium
- Switzerland
- Germany
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden